Literature DB >> 24010950

Comparative evaluation of galactomannan optical density indices and culture results in bronchoscopic specimens obtained from neutropenic and non-neutropenic patients.

Harun Ağca1, Beyza Ener, Emel Yılmaz, Ahmet Ursavaş, Esra Kazak, Vildan Özkocaman, Ezgi Demirdöğen Çetinoğlu, Aslı Görek Dilektaşlı, Halis Akalın, Fahir Özkalemkaş, Rıdvan Ali.   

Abstract

Aspergillus infections are major causes of morbidity and mortality among immunocompromised patients. This study was designed to investigate the galactomannan assay optical density (OD) indices relative to the culture results in bronchoscopic samples obtained from neutropenic and non-neutropenic patients. Galactomannan OD indices from 1427 samples from 2005 to 2012, which were sent from 839 patients and were composed of bronchial lavage (BL = 727) and bronchoalveolar lavage fluids (BAL = 700), were retrospectively analysed. The recovery rates of Aspergillus species from these specimens were 9.4% from the combined patient group and 13.3% from the neutropenic group. Aspergillus fumigatus complex was the most frequently isolated species. The mean and median OD indices of the positive and negative culture samples are approximately 5 and 1, respectively, and 91% of all culture-positive samples have ≥1 OD index value. The receiver-operating characteristics curve analysis demonstrated that the feasibility of the Aspergillus galactomannan assay and Aspergillus galactomannan test has superior accuracy in BAL compared to BL fluids, and the test is not affected by the immune status of the patient. We suggest that the Aspergillus galactomannan test, which uses bronchoscopic material, leads to an earlier diagnosis and if the OD index is found ≥1, fungal growth can be expected.
© 2013 Blackwell Verlag GmbH.

Entities:  

Keywords:  Aspergillus; culture; galactomannan

Mesh:

Substances:

Year:  2013        PMID: 24010950     DOI: 10.1111/myc.12126

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  6 in total

1.  Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis.

Authors:  Mojtaba Taghizadeh-Armaki; Mohammad T Hedayati; Vahid Moqarabzadeh; Saham Ansari; Saeed Mahdavi Omran; Hossein Zarrinfar; Sasan Saber; Paul E Verweij; David W Denning; Seyedmojtaba Seyedmousavi
Journal:  J Med Microbiol       Date:  2017-07-12       Impact factor: 2.472

2.  Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients.

Authors:  Koen de Heer; Marije G Gerritsen; Caroline E Visser; Mariska Mg Leeflang
Journal:  Cochrane Database Syst Rev       Date:  2019-05-20

3.  Diagnosis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-2).

Authors:  Sevtap Arıkan Akdağlı; Alpay Azap; Figen Başaran Demirkazık; Beyza Ener; Sibel Aşcıoğlu Hayran; Özlem Özdemir Kumbasar; Gökhan Metan; Zekaver Odabaşı; Ömrüm Uzun; Hamdi Akan
Journal:  Turk J Haematol       Date:  2014-12-05       Impact factor: 1.831

Review 4.  How to treat fungal infections in ICU patients.

Authors:  Dimitrios K Matthaiou; Theodora Christodoulopoulou; George Dimopoulos
Journal:  BMC Infect Dis       Date:  2015-05-02       Impact factor: 3.090

5.  Serum galactomannan levels in the diagnosis of invasive aspergillosis.

Authors:  Yildiz Okuturlar; Fahir Ozkalemkas; Beyza Ener; Sibel Ocak Serin; Esra Kazak; Tulay Ozcelik; Vildan Ozkocaman; Hasan Atilla Ozkan; Halis Akalin; Meral Gunaldi; Ridvan Ali
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884

6.  The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study

Authors:  Vildan Özkocaman; Fahir Özkalemkaş; Serdar Seyhan; Beyza Ener; Ahmet Ursavaş; Tuba Ersal; Esra Kazak; Ezgi Demirdöğen; Reşit Mıstık; Halis Akalın
Journal:  Turk J Haematol       Date:  2018-07-26       Impact factor: 1.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.